Last reviewed · How we verify
JNJ-56021927 Softgel Capsule — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
JNJ-56021927 Softgel Capsule (JNJ-56021927 Softgel Capsule) — Aragon Pharmaceuticals, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| JNJ-56021927 Softgel Capsule TARGET | JNJ-56021927 Softgel Capsule | Aragon Pharmaceuticals, Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- JNJ-56021927 Softgel Capsule CI watch — RSS
- JNJ-56021927 Softgel Capsule CI watch — Atom
- JNJ-56021927 Softgel Capsule CI watch — JSON
- JNJ-56021927 Softgel Capsule alone — RSS
Cite this brief
Drug Landscape (2026). JNJ-56021927 Softgel Capsule — Competitive Intelligence Brief. https://druglandscape.com/ci/jnj-56021927-softgel-capsule. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab